Pharmaceutical manufacturers have historically focused their activity on large, high-value markets, leaving those in smaller countries struggling to find the latest medicines. New EU legislation is designed to correct that imbalance.
The government needs to take the public into its confidence by communicating clear and truthful information on how it is dealing with medicine shortages